Literature DB >> 21984234

In vitro fermentation of sugar beet arabino-oligosaccharides by fecal microbiota obtained from patients with ulcerative colitis to selectively stimulate the growth of Bifidobacterium spp. and Lactobacillus spp.

Louise Kristine Vigsnæs1, Jesper Holck, Anne S Meyer, Tine Rask Licht.   

Abstract

The potential prebiotic properties of arabino-oligosaccharides (AOS) derived from sugar beet pulp was studied using mixed cultures of human fecal bacteria from patients with ulcerative colitis (UC), in remission or with active disease, and in healthy controls. These results were compared to those for fructo-oligosaccharides (FOS), which are known to have a prebiotic effect. Fermentation studies were carried out using a small-scale static batch system, and changes in the fecal microbial communities and metabolites were monitored after 24 h by quantitative real-time PCR and short-chain fatty acid analysis. With a few minor exceptions, AOS affected the communities similarly to what was seen for FOS. Quantitative real-time PCR revealed that Bifidobacterium spp. and Lactobacillus spp. were selectively increased after fermentation of AOS or FOS by fecal microbiota derived from UC patients. The stimulation of growth of Lactobacillus spp. and Bifidobacterium spp. was accompanied by a high production of acetate and hence a decrease of pH. The fermentation of AOS may help improve the inflammatory conditions in UC patients through stimulation of bacteria eliciting anti-inflammatory responses and through production of acetate. AOS may therefore represent a new prebiotic candidate for reduction of the risk of flare-ups in UC patients. However, human trials are needed to confirm a health-promoting effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984234      PMCID: PMC3233050          DOI: 10.1128/AEM.05895-11

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  66 in total

1.  In vitro fermentation of sugar beet arabinan and arabino-oligosaccharides by the human gut microflora.

Authors:  M A H M Al-Tamimi; R J Palframan; J M Cooper; G R Gibson; R A Rastall
Journal:  J Appl Microbiol       Date:  2006-02       Impact factor: 3.772

2.  Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis.

Authors:  Federico Lara-Villoslada; Oscar de Haro; Desire Camuesco; Mónica Comalada; Javier Velasco; Antonio Zarzuelo; Jordi Xaus; Julio Galvez
Journal:  Eur J Nutr       Date:  2006-07-26       Impact factor: 5.614

3.  Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis.

Authors:  S U Christl; H D Eisner; G Dusel; H Kasper; W Scheppach
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Feruloylated and nonferuloylated arabino-oligosaccharides from sugar beet pectin selectively stimulate the growth of Bifidobacterium spp. in human fecal in vitro fermentations.

Authors:  Jesper Holck; Andrea Lorentzen; Louise K Vigsnæs; Tine R Licht; Jørn D Mikkelsen; Anne S Meyer
Journal:  J Agric Food Chem       Date:  2011-05-25       Impact factor: 5.279

5.  In vitro evaluation of the prebiotic activity of a pectic oligosaccharide-rich extract enzymatically derived from bergamot peel.

Authors:  G Mandalari; C Nueno Palop; K Tuohy; G R Gibson; R N Bennett; K W Waldron; G Bisignano; A Narbad; C B Faulds
Journal:  Appl Microbiol Biotechnol       Date:  2006-10-05       Impact factor: 4.813

6.  A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides.

Authors:  C E Rycroft; M R Jones; G R Gibson; R A Rastall
Journal:  J Appl Microbiol       Date:  2001-11       Impact factor: 3.772

7.  In vitro investigation into the potential prebiotic activity of honey oligosaccharides.

Authors:  María Luz Sanz; Nikolaos Polemis; Valle Morales; Nieves Corzo; Alexandra Drakoularakou; Glenn R Gibson; Robert A Rastall
Journal:  J Agric Food Chem       Date:  2005-04-20       Impact factor: 5.279

8.  Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease.

Authors:  J O Lindsay; K Whelan; A J Stagg; P Gobin; H O Al-Hassi; N Rayment; M A Kamm; S C Knight; A Forbes
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

9.  Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR.

Authors:  Jean-Marc Delroisse; Anne-Lise Boulvin; Isabelle Parmentier; Robin Dubois Dauphin; Micheline Vandenbol; Daniel Portetelle
Journal:  Microbiol Res       Date:  2008       Impact factor: 5.415

10.  Alternative pathways for hydrogen disposal during fermentation in the human colon.

Authors:  G R Gibson; J H Cummings; G T Macfarlane; C Allison; I Segal; H H Vorster; A R Walker
Journal:  Gut       Date:  1990-06       Impact factor: 23.059

View more
  19 in total

1.  In situ prebiotics for weaning piglets: in vitro production and fermentation of potato galacto-rhamnogalacturonan.

Authors:  Mikael Lenz Strube; Helle Christine Ravn; Hans-Christian Ingerslev; Anne Strunge Meyer; Mette Boye
Journal:  Appl Environ Microbiol       Date:  2014-12-19       Impact factor: 4.792

2.  Prebiotics from acorn and sago prevent high-fat-diet-induced insulin resistance via microbiome-gut-brain axis modulation.

Authors:  Shokouh Ahmadi; Ravinder Nagpal; Shaohua Wang; Jason Gagliano; Dalane W Kitzman; Sabihe Soleimanian-Zad; Mahmoud Sheikh-Zeinoddin; Russel Read; Hariom Yadav
Journal:  J Nutr Biochem       Date:  2019-01-30       Impact factor: 6.048

Review 3.  Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.

Authors:  Zi-Kai Wang; Yun-Sheng Yang; Ye Chen; Jing Yuan; Gang Sun; Li-Hua Peng
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

4.  Dietary xylo-oligosaccharide stimulates intestinal bifidobacteria and lactobacilli but has limited effect on intestinal integrity in rats.

Authors:  Ellen Gerd Christensen; Tine Rask Licht; Thomas Dyrmann Leser; Martin Iain Bahl
Journal:  BMC Res Notes       Date:  2014-09-19

5.  Effects of xylo-oligosaccharide and flavomycin on the immune function of broiler chickens.

Authors:  Lin Yuan; Wanli Li; Qianqian Huo; Chenhong Du; Zhixiang Wang; Baodi Yi; Mingfa Wang
Journal:  PeerJ       Date:  2018-03-05       Impact factor: 2.984

6.  Cyprus Sausages' Bacterial Community Identification Through Metataxonomic Sequencing: Evaluation of the Impact of Different DNA Extraction Protocols on the Sausages' Microbial Diversity Representation.

Authors:  Eleni Kamilari; Marina Efthymiou; Dimitrios A Anagnostopoulos; Dimitrios Tsaltas
Journal:  Front Microbiol       Date:  2021-05-17       Impact factor: 5.640

7.  Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus.

Authors:  Louise Kristine Vigsnaes; Pieter van den Abbeele; Karolina Sulek; Henrik Lauritz Frandsen; Casper Steenholdt; Jørn Brynskov; Joan Vermeiren; Tom van de Wiele; Tine Rask Licht
Journal:  Sci Rep       Date:  2013-01-23       Impact factor: 4.379

8.  Differential responses of gut microbiota to the same prebiotic formula in oligotrophic and eutrophic batch fermentation systems.

Authors:  Wenmin Long; Zhengsheng Xue; Qianpeng Zhang; Zhou Feng; Laura Bridgewater; Linghua Wang; Liping Zhao; Xiaoyan Pang
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

9.  Equol status and changes in fecal microbiota in menopausal women receiving long-term treatment for menopause symptoms with a soy-isoflavone concentrate.

Authors:  Lucía Guadamuro; Susana Delgado; Begoña Redruello; Ana B Flórez; Adolfo Suárez; Pablo Martínez-Camblor; Baltasar Mayo
Journal:  Front Microbiol       Date:  2015-08-05       Impact factor: 5.640

Review 10.  Oligosaccharides: a boon from nature's desk.

Authors:  Seema A Belorkar; A K Gupta
Journal:  AMB Express       Date:  2016-10-03       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.